[go: up one dir, main page]

TN2012000473A1 - Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs - Google Patents

Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Info

Publication number
TN2012000473A1
TN2012000473A1 TNP2012000473A TN2012000473A TN2012000473A1 TN 2012000473 A1 TN2012000473 A1 TN 2012000473A1 TN P2012000473 A TNP2012000473 A TN P2012000473A TN 2012000473 A TN2012000473 A TN 2012000473A TN 2012000473 A1 TN2012000473 A1 TN 2012000473A1
Authority
TN
Tunisia
Prior art keywords
robo1
tumors
treatment
fusion protein
protein
Prior art date
Application number
TNP2012000473A
Other languages
English (en)
Inventor
Francis Blanche
Béatrice Cameron
Tarik Dabdoubi
Frédérique Dol-Gleizes
Pierre Fons
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000473(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TN2012000473A1 publication Critical patent/TN2012000473A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne une protéine recombinante Robo1-Fc et son utilisation pour traiter les maladies dans lesquelles une protéine Slit est surexprimée, en particulier le cancer. Elle concerne également une composition comprenant une telle protéine recombinante. Un autre aspect de l'invention consiste en l'utilisation d'une molécule Robo1-Fc en tant qu'outil de diagnostic pour détecter la surexpression d'une molécule de la famille Slit chez un patient.
TNP2012000473A 2010-04-14 2012-09-28 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs TN2012000473A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
PCT/FR2011/050811 WO2011128561A1 (fr) 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
TN2012000473A1 true TN2012000473A1 (fr) 2014-01-30

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000473A TN2012000473A1 (fr) 2010-04-14 2012-09-28 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Country Status (27)

Country Link
US (1) US9493529B2 (fr)
EP (1) EP2558489A1 (fr)
JP (1) JP5858442B2 (fr)
KR (1) KR20130059329A (fr)
CN (1) CN102884076A (fr)
AR (1) AR080891A1 (fr)
AU (1) AU2011239839B2 (fr)
BR (1) BR112012026020A2 (fr)
CA (1) CA2796303A1 (fr)
CL (1) CL2012002879A1 (fr)
CR (1) CR20120508A (fr)
DO (1) DOP2012000265A (fr)
EA (1) EA201291044A1 (fr)
EC (1) ECSP12012230A (fr)
FR (1) FR2958936A1 (fr)
GT (1) GT201200275A (fr)
IL (1) IL222382A (fr)
MA (1) MA34221B1 (fr)
MX (1) MX338981B (fr)
NI (1) NI201200155A (fr)
PE (1) PE20130199A1 (fr)
PH (1) PH12012502044A1 (fr)
SG (1) SG184529A1 (fr)
TN (1) TN2012000473A1 (fr)
TW (1) TW201142024A (fr)
UY (1) UY33334A (fr)
WO (1) WO2011128561A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE175248T1 (de) 1993-04-05 1999-01-15 Daikin Ind Ltd Polytetrafluorethylenfaser, baumwollartiges, diese faser enthaltendes material, und verfahren zu deren herstellung
PH12013501205A1 (en) * 2010-12-23 2013-07-29 Sanofi Sa Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
TR201821294T4 (tr) 2012-01-05 2019-01-21 Boston Medical Ct Corp Böbrek Hastalığının Teşhisi Ve Tedavisine Yönelik Slit-robo Sinyal İletimi
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
AU2018278809B2 (en) 2017-06-02 2022-03-31 Boston Medical Center Corporation Recombinant ROBO2 proteins, compositions, methods and uses thereof
US11406682B2 (en) 2017-08-24 2022-08-09 Bar-Ilan University Roundabout (Robo) receptor inhibitors and uses thereof
CN113557034B (zh) * 2019-02-27 2024-10-01 株式会社大熊制药 包含与白蛋白结合的Slit3蛋白的LRRD2的用于预防或治疗骨相关疾病的组合物
BR112021021092A2 (pt) 2019-04-23 2023-02-28 Univ California Composições e métodos úteis na promoção de produção de leite
WO2025056020A1 (fr) * 2023-09-14 2025-03-20 北京拓界生物医药科技有限公司 Protéine contenant un domaine robo et son utilisation médicale

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
EP1025231B1 (fr) * 1997-10-20 2003-07-16 The Regents of the University of California Robo : une famille de polypeptides et d'acides nucleiques impliques dans le guidage des nerfs
WO1999051625A2 (fr) 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides provoquant la formation de structures compactes
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
SI1572169T1 (sl) 2002-03-08 2013-12-31 Shanghai Institutes For Biological Sciences, Cas Odkrivanje in modulacija slit in robo posredovane angiogeneze ter njuni načini uporabe
WO2005014818A1 (fr) * 2003-08-08 2005-02-17 Perseus Proteomics Inc. Gene surexprime dans le cancer
JP2008504012A (ja) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質
AU2007235484B2 (en) * 2006-04-05 2013-11-07 Abbvie Biotechnology Ltd Antibody purification
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
TW200902547A (en) * 2007-04-27 2009-01-16 Genentech Inc Potent, stable and non-immunosuppressive anti-CD4 antibodies
HRP20180873T1 (hr) 2007-08-29 2018-07-13 Sanofi Humanizirana anti-cxcr5 protutijela, njihovi derivati i njihova upotreba
EP2050764A1 (fr) * 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent

Also Published As

Publication number Publication date
GT201200275A (es) 2014-01-24
ECSP12012230A (es) 2012-11-30
CR20120508A (es) 2012-11-01
EA201291044A1 (ru) 2013-04-30
PH12012502044A1 (en) 2017-07-26
FR2958936A1 (fr) 2011-10-21
KR20130059329A (ko) 2013-06-05
SG184529A1 (en) 2012-11-29
DOP2012000265A (es) 2013-02-28
AR080891A1 (es) 2012-05-16
CA2796303A1 (fr) 2011-10-20
EP2558489A1 (fr) 2013-02-20
MX338981B (es) 2016-05-06
US9493529B2 (en) 2016-11-15
JP5858442B2 (ja) 2016-02-10
TW201142024A (en) 2011-12-01
WO2011128561A1 (fr) 2011-10-20
JP2013523172A (ja) 2013-06-17
MX2012011822A (es) 2012-11-12
BR112012026020A2 (pt) 2016-06-28
US20130039912A1 (en) 2013-02-14
PE20130199A1 (es) 2013-03-09
MA34221B1 (fr) 2013-05-02
NI201200155A (es) 2013-02-05
AU2011239839A1 (en) 2012-11-08
UY33334A (es) 2011-12-01
IL222382A (en) 2016-06-30
IL222382A0 (en) 2012-12-31
CN102884076A (zh) 2013-01-16
AU2011239839B2 (en) 2015-08-20
CL2012002879A1 (es) 2013-03-22

Similar Documents

Publication Publication Date Title
TN2012000473A1 (fr) Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2008101985A3 (fr) Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
WO2007091250A8 (fr) Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
WO2004108139A8 (fr) Utilisation de composes heterocycliques en tant qu'inhibiteurs de scce
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
DE60028970D1 (de) An her2 bindende peptidverbindungen
CL2012000592A1 (es) Compuestos derivados de fenoxi o fenil-tieno[3,2-b]piridina, inhibidores de tirosina quinasas; composicion farmaceutica; y su uso en el tratamiento de cancer colorrectal, de pulmon, hematologico, de higado, mama, en retinopatia diabetica, degeneracion macular, glaucoma, psoriasis, diabetes, enfermedades neurodegenerativas, entre otras.
NO20054958L (no) Substitulerte aminokarboksylsyrer
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
NO20054957L (no) Subtituerte karboksylsyrer
EP2285989A4 (fr) Nouvelles cibles permettant de réguler l'angiogenèse
WO2008153933A3 (fr) Protéines à variante d'épissure her2 et her3 solubles, oligonucléotides à permutation d'épissage et leur utilisation thérapeutique
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
TW200630327A (en) Substituted phenylalkanoic acids
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2001071357A3 (fr) Proteines, genes et leur utilisation pour diagnostiquer et traiter le cancer de la poitrine
WO2009105457A3 (fr) Marqueurs du cancer slit2
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
Zhu et al. Inhibition of PINK1 senses ROS signaling to facilitate neuroblastoma cell pyroptosis
EP4218786A3 (fr) Opiorphine destinée à être utilisée comme agent analgésique
MA34480B1 (fr) Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires
TW200631949A (en) Substituted carboxylic acids